Gynecologic Oncology Reports最新文献

{"title":"Experience of healthcare discrimination reported by individuals with a history of gynecologic cancer in the All of Us research program","authors":"Allison C. Dona ,&nbsp;Patricia I. Jewett ,&nbsp;Sarah Davidson ,&nbsp;Deanna Teoh ,&nbsp;Rachel I. Vogel","doi":"10.1016/j.gore.2025.101723","DOIUrl":"10.1016/j.gore.2025.101723","url":null,"abstract":"<div><h3>Objective</h3><div>We aimed to describe prevalence of healthcare discrimination in <em>All of Us</em> participants with a history of gynecologic cancer and compare patient experiences of discrimination by gynecologic cancer type.</div></div><div><h3>Methods</h3><div>We analyzed survey data of participants with a history of gynecologic cancer in the <em>All of Us Research Program</em>. Cancer status was defined using self-report or electronic health record documentation. Healthcare discrimination was measured by the Discrimination in Medical Settings (DMS) Scale. Potential confounders were self-reported (cigarette use, sexual orientation, gender, race, ethnicity, income, education, and age) and physical measurement (body mass index). We report associations between gynecologic cancer site (cervical, ovarian, uterine, vaginal or vulvar, more than one) and DMS scores using multivariable logistic regression.</div></div><div><h3>Results</h3><div>Of 2,195 participants, 1,001 had cervical, 579 uterine, 419 ovarian, 30 vaginal/vulvar, and 166 more than one gynecologic cancer. Most (76.5%) reported experiencing any healthcare discrimination, and 45.0% reported frequent healthcare discrimination. Those with a history of cervical cancer (52%, OR: 1.80, 95% CI: 1.42, 2.28) and multiple cancers (47.8%, OR: 1.53, 95% CI: 1.05, 2.21) had higher odds of frequently reporting discrimination than those with a history of ovarian cancer (37.5%) in the unadjusted model. The relationship observed remained but was attenuated in the adjusted model (Cervical OR: 1.35, 95% CI: 1.04, 1.75; Multiple OR: 1.35 95% CI: 0.91, 2.00).</div></div><div><h3>Conclusions</h3><div>Healthcare discrimination was reported across cancer types. Individuals with a history of cervical or multiple gynecologic malignancies reported frequent healthcare discrimination more often than those with other gynecologic cancers.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"58 ","pages":"Article 101723"},"PeriodicalIF":1.2,"publicationDate":"2025-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143685970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psychological impact of risk-reducing surgery for gynecologic cancer among women with Lynch syndrome","authors":"Helen Huband ,&nbsp;Kaitlin M McGarragle ,&nbsp;Crystal J Hare ,&nbsp;Melyssa Aronson ,&nbsp;Thomas Ward ,&nbsp;Kara Semotiuk ,&nbsp;Sarah E Ferguson ,&nbsp;Zane Cohen ,&nbsp;Tae L Hart","doi":"10.1016/j.gore.2025.101719","DOIUrl":"10.1016/j.gore.2025.101719","url":null,"abstract":"<div><h3>Objective</h3><div>Prophylactic total hysterectomy and bilateral salpingo-oophorectomy are risk-reducing surgeries (RRS) that can be offered to women with Lynch syndrome (LS) as they reduce the incidence of ovarian and endometrial cancer. Few studies have examined facilitators to RRS or the experiences of women with LS post-surgery. This qualitative study explored the experiences of women with LS who underwent RRS.</div></div><div><h3>Methods</h3><div>Women with LS who had undergone RRS within the prior 10 years were recruited from a genetic cancer registry and a tertiary care medical centre in Canada. Participants completed interviews over the phone. A qualitative descriptive methodological approach was taken, and interviews were analyzed using thematic analysis.</div></div><div><h3>Results</h3><div>Fifteen participants completed interviews. Themes identified included: 1) facilitators to RRS including desire for peace of mind, completed family planning, presence of physical symptoms associated with gynecologic cancer, burden of screening, personal or family history of cancer, age, and trust in healthcare providers (HCPs); 2) women’s experiences with RRS including post-surgical recovery, long-term physical changes post-surgery, impact of surgery on sexual health, psychological impacts of managing risk, and post-surgical care from HCPs; 3) experiences managing menopausal symptoms and use of hormone replacement therapy; and 4) unmet informational needs including managing expectations prior to surgery, understanding risk related to other health conditions, and questions about the ongoing need for gynecologic cancer surveillance.</div></div><div><h3>Conclusions</h3><div>HCPs should consider facilitators to surgery in women with LS contemplating RRS. HCPs should also provide women with LS more detailed post-surgery information on what to expect, and risks of other health conditions.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"58 ","pages":"Article 101719"},"PeriodicalIF":1.2,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143685893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oncologic and fertility outcome in patients with advanced stage ovarian immature teratomas","authors":"Marino Giuseppe ,&nbsp;Negri Serena ,&nbsp;Testa Filippo ,&nbsp;Giuliani Daniela ,&nbsp;De Ponti Elena ,&nbsp;Bombelli Martina ,&nbsp;Giorgia Pecis Cavagna ,&nbsp;Lugotti Daniele ,&nbsp;Jaconi Marta ,&nbsp;Casiraghi Alessandra ,&nbsp;Bianchi Tommaso ,&nbsp;Grassi Tommaso ,&nbsp;Bonazzi Maria Cristina ,&nbsp;Fruscio Robert","doi":"10.1016/j.gore.2025.101715","DOIUrl":"10.1016/j.gore.2025.101715","url":null,"abstract":"<div><h3>Background</h3><div>Immature teratomas represent rare malignant ovarian germ cell tumours, typically involving young women<em>.</em> The majority of germ cell tumors (60%–70%) are diagnosed at an early stage, showing an optimal prognosis. However, advanced stages represent about one third of these patients. We report the oncologic outcome of this population, investigating also fertility outcomes in patients who underwent fertility preservation.</div></div><div><h3>Methods</h3><div>Clinicopathological data were retrospectively collected and analysed from a cohort of 17 post-pubertal patients with advanced stage immature teratomas in a single centre between 1980 and 2024.</div></div><div><h3>Results</h3><div>Among 17 patients included in the study, 76.5 % (13/17) underwent fertility-sparing surgery (FSS) and 23.5 % (4/17) radical surgery. Adjuvant chemotherapy was administered in 82 % (14/17) of patients. After a median follow up of 237 months (range 68.0–289.0), 2 patients had persistent disease after receiving chemotherapy and 3 showed relapse. Of these, two had a second relapse. All patients are alive without evidence of disease at the last follow up. Also 46 % (6/13) of women treated with FSS reached pregnancy.</div></div><div><h3>Conclusions</h3><div>FSS appears to be safe and effective in the treatment of advanced stage immature teratoma. Despite surgical interventions and the administration of chemotherapy in the majority of patients, fertility outcome is satisfactory.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"58 ","pages":"Article 101715"},"PeriodicalIF":1.2,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143620164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long term treatment of advanced endometrial cancer with lenvatinib and pembrolizumab","authors":"Sahana Somasegar,&nbsp;Becky Sousa MSN,&nbsp;Arati Jairam-Thodla,&nbsp;Oliver Dorigo","doi":"10.1016/j.gore.2025.101717","DOIUrl":"10.1016/j.gore.2025.101717","url":null,"abstract":"<div><h3>Objective</h3><div>To describe a case of sustained disease control for over five years in a patient with recurrent, advanced endometrial cancer treated with lenvatinib and pembrolizumab, despite significant treatment-related toxicities.</div></div><div><h3>Methods</h3><div>We present a 49-year-old patient with grade 3, stage IVB endometrioid endometrial adenocarcinoma. After cytoreductive surgery, carboplatin and paclitaxel chemotherapy, and radiation therapy, the patient experienced progression with widespread metastases. She was then treated with lenvatinib (20 mg daily) and pembrolizumab (200 mg every three weeks). The patient experienced multiple treatment-related adverse events, including hypertension, colitis, hypothyroidism, adrenal insufficiency, and ocular toxicity, requiring dose adjustments and treatment interruptions.</div></div><div><h3>Results</h3><div>Despite frequent toxicities, the patient achieved a durable response to lenvatinib and pembrolizumab. Five years after treatment initiation, imaging showed no metabolically active disease, with only minimal stable residual lesions. Careful management of adverse effects, including supportive care, dose modifications, and temporary treatment pauses, enabled continued therapy.</div></div><div><h3>Conclusion</h3><div>This case underscores the potential for long-term disease control with lenvatinib and pembrolizumab in advanced endometrial cancer, even in patients with proficient mismatch repair (pMMR) and low tumor mutational burden. Although toxicities can require treatment adjustments, they can often be effectively managed, allowing for prolonged therapy. Further research is needed to determine the optimal treatment duration and strategies to mitigate long-term side effects.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"58 ","pages":"Article 101717"},"PeriodicalIF":1.2,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143577586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diverse case series of granulomatous peritonitis mimicking advanced ovarian cancer","authors":"Rachel L. Furuya ,&nbsp;Bobbie J. Rimel ,&nbsp;Richard Tsai ,&nbsp;Rebecca Ann Brooks ,&nbsp;L. Stewart Massad ,&nbsp;Premal H. Thaker ,&nbsp;John D. Pfeifer","doi":"10.1016/j.gore.2025.101712","DOIUrl":"10.1016/j.gore.2025.101712","url":null,"abstract":"<div><h3>Background</h3><div>Epithelial ovarian cancer commonly presents with vague symptoms that delay diagnosis until disease is advanced. Granulomatous peritonitis is a term used to describe granulomatous inflammation within the peritoneal cavity and mimics advanced stage ovarian cancer clinically and on imaging. The goal of this study was to examine the frequency and characteristics of cases of granulomatous peritonitis mimicking ovarian cancer at a single institution and to describe the etiology in this population.</div></div><div><h3>Methods</h3><div>Eight cases were identified with pathology conformation of granulomatous disease and absence of cancer. The etiologies include pelvic tuberculosis, ruptured dermoid cyst, ruptured hemorrhagic corpus luteum, prior endometriosis surgery, xanthogranulomatous inflammation and three cases of tubo-ovarian abscesses.</div></div><div><h3>Results</h3><div>Seven of the eight had pelvic masses on imaging studies; one patient had presumed carcinomatosis without an adnexal mass on CT scan. Preoperative CA-125 was elevated in four of the eight patients, with a range of 30.8 to 228 U/mL. All had some form of surgical management with at least one ovary removed.</div></div><div><h3>Conclusion</h3><div>Clinicians should be aware of this disease to improve diagnosis and direct appropriate patient management.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"58 ","pages":"Article 101712"},"PeriodicalIF":1.2,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143620163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The challenge of managing isolated STIC lesions: A single-center experience","authors":"Renata Sabelli ,&nbsp;Basile Tessier-Cloutier ,&nbsp;Lili Fu ,&nbsp;Shuk On Annie Leung ,&nbsp;Xing Zeng ,&nbsp;Reitan Ribeiro ,&nbsp;Victoria Mandilaras ,&nbsp;Lucy Gilbert ,&nbsp;Laurence Bernard","doi":"10.1016/j.gore.2025.101716","DOIUrl":"10.1016/j.gore.2025.101716","url":null,"abstract":"<div><h3>Objectives</h3><div>High-grade serous carcinoma (HGSC) arise from serous tubal intraepithelial carcinoma (STIC) lesions, a precursor that develops from the fallopian tube epithelium. Patients with incidental isolated STIC lesions found on salpingectomy specimen have up to 25% risk of developing HGSC or peritoneal carcinomatosis in the future, yet there is no established consensus to guide management.</div></div><div><h3>Methods</h3><div>This retrospective case series includes patients diagnosed with isolated STIC lesions between April 2017 and January 2024. Patient data was extracted from clinical and pathological databases.</div></div><div><h3>Results</h3><div>During the study period, 10 patients were diagnosed with an isolated STIC lesion. The fallopian tubes were removed either as part of a hysterectomy for endometrial cancer (n = 3); a prophylactic risk-reducing surgery for <em>BRCA1</em> or <em>BRCA2</em> mutation (n = 3); or a benign gynecologic condition (n = 4). The median age of the patients was 64 years (range: 53–80). Among patients who underwent genetic testing (n = 9), only three were found to have a deleterious germline mutation in <em>BRCA1</em> or <em>BRCA2</em>. The patients either received adjuvant chemotherapy (n = 5) or underwent active surveillance (n = 5). One surveillance patient was managed with completion bilateral oophorectomy and omentectomy. Median number of chemotherapy cycles was four (range 4–6 cycles). The median follow-up was 27 months (range: 5–83 months). One patient under active surveillance was diagnosed with peritoneal carcinomatosis 5 years after initial diagnosis of STIC whereas none recurred in the chemotherapy group.</div></div><div><h3>Conclusion</h3><div>The wide variety of treatment approaches we observed highlights a need for more data on this entity to support management guidelines.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"58 ","pages":"Article 101716"},"PeriodicalIF":1.2,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143609737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fertility-sparing treatment for atypical polypoid adenomyoma","authors":"Isabel Beshar ,&nbsp;Susan Lang ,&nbsp;Oliver Dorigo ,&nbsp;Brooke E Howitt ,&nbsp;Caroline Liu ,&nbsp;Amer Karam","doi":"10.1016/j.gore.2025.101714","DOIUrl":"10.1016/j.gore.2025.101714","url":null,"abstract":"<div><h3>Introduction</h3><div>Atypical polypoid adenomyoma (APA) has classically been described as a benign lesion of the endometrium; however, recent studies have identified risk of progression to malignant pathology. Standard treatment includes hysterectomy but since many patients with APA are young and desire fertility, uterine-sparing options have been explored. In this study, we examine long-term outcomes of fertility-sparing treatment, including hysteroscopic resection and progesterone therapy, on progression to hyperplasia or endometrial carcinoma.</div></div><div><h3>Methods</h3><div>We performed a retrospective cohort study of patients with APA from January 1st 2000 to December 31st 2023 at our quaternary care center. Sociodemographic factors, treatment options (including hysterectomy, hysteroscopy, chemoradiation, and/or hormonal therapy), pathology pre- and post-treatment, and live birth rates, were abstracted from the record. Institutional review board approval was obtained prior to data collection.</div></div><div><h3>Results</h3><div>Sixty-six patients were included in our study time-period. One in three patients (n = 37, 60.7 %) in our cohort opted for fertility-sparing treatment, especially among young (mean age 33.6), nulliparous patients. Most patients underwent hysteroscopic resection (70.8 %), compared to progesterone-only therapy (16.7 % with intrauterine device (IUD)<!--> <!-->and 12.5 % with oral progesterone). Over two decades, 33.3 % of our cohort progressed to hyperplasia or carcinoma; 29.2 % had persistence of APA pathology; and 33.3 % had resolution of APA. On average, patients progressed within 4.5 years of therapy. There were three births.</div></div><div><h3>Discussion</h3><div>High rates of resolution of APA pathology were observed amongst those undergoing hysteroscopic resection with or without placement of IUD. While not statistically significant due to our sample size, lower rates of resolution were observed among those on hormonal therapy alone, especially oral progesterone.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"58 ","pages":"Article 101714"},"PeriodicalIF":1.2,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143562223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effect of isolated tumor cells on adjuvant treatment decisions for patients with endometrial cancer: A retrospective case series","authors":"Camryn Kenkel ,&nbsp;Sarah S. Lee ,&nbsp;Naaman Mehta ,&nbsp;Jude Nawlo ,&nbsp;Edward Jimenez ,&nbsp;Leslie R. Boyd","doi":"10.1016/j.gore.2025.101713","DOIUrl":"10.1016/j.gore.2025.101713","url":null,"abstract":"<div><h3>Objective</h3><div>Sentinel lymph node biopsy (SLNB) for endometrial cancer staging may identify isolated tumor cells (ITCs). Although guidelines do not classify nodes with ITCs as positive, earlier papers reported that a significant proportion of gynecologic oncologists treat ITCs as they would positive nodes. The objective of this study was to examine practice patterns and determine if the presence of ITCs in endometrial cancer affects adjuvant treatment decision-making.</div></div><div><h3>Methods</h3><div>This was a retrospective series of patients with endometrial adenocarcinoma stages I to IIIB who underwent surgical staging with SNLB from July 2016 to January 2022 at three hospitals. The primary outcome of interest was the receipt of adjuvant treatment. Chi-square, Mann-Whitney <em>U</em> test, and logistic regression were used with significance set at p &lt; 0.05.</div></div><div><h3>Results</h3><div>Of seven hundred thirty-four patients included, ITCs were identified in 41 patients (5.6 %). Deep myometrial invasion (61.0 % vs 20.5 %, p &lt; 0.001) and lymphovascular invasion (58.4 % vs 17.7 %, p &lt; 0.001) were more common in patients with ITCs than in those with negative lymph nodes. Patients with ITCs were more likely to receive adjuvant treatment (30 of 41, 73.2 % vs 289 of 693, 41.7 %, p &lt; 0.001). When controlling for age, stage, histology, grade, and lymphovascular space invasion, ITCs were not associated with an increased likelihood of adjuvant therapy receipt.</div></div><div><h3>Conclusions</h3><div>Although patients with ITCs were more likely to receive adjuvant treatment, this was accounted for by other clinical and histological factors. Clinicians were likely to make decisions based on established risk factors, and more data are needed on the role of ITCs in the landscape of molecularly based decision making.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"58 ","pages":"Article 101713"},"PeriodicalIF":1.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143609738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oligometastatic granulosa cell tumor treated with stereotactic body radiation therapy with a radiographic and tumor marker response","authors":"Madeline Petty ,&nbsp;Vasanti Jhaveri ,&nbsp;Nicholas Taylor ,&nbsp;Benjamin Foster","doi":"10.1016/j.gore.2025.101708","DOIUrl":"10.1016/j.gore.2025.101708","url":null,"abstract":"<div><div>Stereotactic body radiation therapy (SBRT) is a safe and effective treatment for oligometastatic gynecologic cancers. This report details the case of a 75-year-old woman with recurrent granulosa cell tumor of the left ovary. The patient was diagnosed with a peritoneal recurrence after her inhibin-B level increased to 39.7 pg/mL, and a subsequent computed tomography (CT) scan of the abdomen and pelvis revealed an enlarging left-sided soft tissue mass in the sigmoid mesentery measuring 1.2 × 1.2 cm. She underwent SBRT, delivering 37.5 Gy in 5 fractions to the soft tissue mass. A CT scan post-treatment indicated the mass had decreased to 0.8 cm and that her inhibin B level decreased to &lt; 7 pg/mL. This case highlights the effectiveness of SBRT in the management of oligometastatic ovarian cancer, achieving a marked radiographic and tumor marker response in patients with disease not amenable to surgical resection.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"58 ","pages":"Article 101708"},"PeriodicalIF":1.2,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143519482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cervical cancer in women under age 40: A cohort study of clinicopathological characteristics and fertility-sparing surgery outcomes","authors":"Matthew Flint ,&nbsp;Francesca Yi ,&nbsp;Mona Saleh ,&nbsp;Xulei Liu ,&nbsp;Stephanie V. Blank ,&nbsp;Yuxin Liu","doi":"10.1016/j.gore.2025.101710","DOIUrl":"10.1016/j.gore.2025.101710","url":null,"abstract":"<div><h3>Objectives</h3><div>The clinical management of cervical cancer patients under age 40 presents unique challenges, requiring a balance between complete cancer resection and fertility preservation. This study aimed to report on the clinicopathological characteristics of a cohort of young patients, along with the oncologic and reproductive outcomes of those who underwent fertility-sparing surgery (FSS).</div></div><div><h3>Methods</h3><div>The pathology database at a single institution was searched for women under age 40 who were diagnosed with invasive cervical cancer between 2015 and 2022. Electronic medical charts were reviewed for demographics, tumor characteristics, clinical management, and surveillance. Statistical analysis was performed using Wilcoxon rank-sum test and chi square test.</div></div><div><h3>Results</h3><div>A total of 57 patients (median age: 34 years; range: 27–40 years) met the inclusion criteria. Cancer histology included squamous cell carcinoma (70 %), adenocarcinoma (28 %), and adenosquamous carcinoma (2 %). The FIGO stage was I (72 %), II (7 %), III (19 %), and IV (2 %). The sensitivity of cytology was 67 %, with notably low significantly for adenocarcinoma (38 %). HPV vaccination documentation was missing for 44 patients (77 %). Among the 16 patients with stage I cancer who underwent FSS, one experienced cancer recurrence (7 %), and four successfully achieved pregnancy.</div></div><div><h3>Conclusions</h3><div>Our cohort study of young cervical cancer patients highlights deficiencies in cervical cancer prevention, including limitations in cytology-based screening and inconsistent documentation of HPV vaccination. FSS offers a promising approach, with low cancer recurrence rates and encouraging pregnancy outcomes.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"58 ","pages":"Article 101710"},"PeriodicalIF":1.2,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143511240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}